Skip to main
CLPT
CLPT logo

CLPT Stock Forecast & Price Target

CLPT Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

ClearPoint Neuro Inc has demonstrated a robust growth trajectory, closing 2023 with a 17% increase in topline revenue while significantly reducing cash burn, indicating improved operational efficiency. The company is poised for continued success in 2024, with expectations of at least 20% revenue growth driven by an expanding partnership network and enhanced service offerings in the Biologics segment. Furthermore, recent key product approvals and record system installations, supported by favorable clinical publications, enhance the positive outlook for the company's future financial performance.

Bears say

ClearPoint Neuro has demonstrated a significant reduction in cash burn, decreasing from $5.8 million in the first quarter of 2023 to $1.2 million by the fourth quarter of the same year. Despite this positive trend, the ongoing reliance on cash reserves raises concerns about the company's ability to fund future growth and operations, particularly in a capital-intensive sector. Additionally, an overall negative sentiment may stem from the company's financial stability, underscoring the need for more consistent revenue generation and profitability to support its long-term viability.

CLPT has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Clearpoint Neuro Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Clearpoint Neuro Inc (CLPT) Forecast

Analysts have given CLPT a Strong Buy based on their latest research and market trends.

According to 3 analysts, CLPT has a Strong Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Clearpoint Neuro Inc (CLPT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.